Progenics Pharmaceuticals, Inc. (PGNX) reported fourth quarter EPS of ($0.18) before the opening bell Monday, compared to the consensus estimate of ($0.13). Revenues declined nearly 120% from last year to ($0.57) million. Analysts expected revenues of $2.8 million.
For the year-end 2014, the company reported net income of $4.4 million, or $0.06 per share, compared to net loss of $42.6 million or $0.76/shr in FY/13. Revenue was reported as $44.4 billion.
On valuation measures, Progenics Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 742K shares, trade at a trailing-12 P/E of 59.08 and a P/E to growth ratio of 2.18. The median Wall Street price target on the name is $10.00 with a high target of $11.00. Currently ticker boasts 2 ‘Buy’ endorsements, compared to 1 ’Hold’ and no ‘Sell’.
Profitability-wise, PGNX has a t-12 profit and operating margin of 16.77% and 5.18%, respectively. The $493.14 million market cap company reported $119.3 million in cash in its most recent quarter.
PGNX currently prints a one year return of 62.61% and a year-to-date loss of around 6.20%.
Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company was founded in 1986 and is based in Tarrytown, New York.